IR News
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
FinancesFY2026 First Quarter Results Briefing Session - Script
-
FinancesFY2026 First Quarter Results Briefing Session - Material
-
FinancesFY2026-Q1 Financial Report (Apr. 1-Jun. 30, 2026)
-
CorporateNotice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock CompensationView PDF
-
R&DGivinostat Update - Movie
-
ProductsJCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGOTM, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter SyndromeView PDF
-
R&DGivinostat Update - script
-
R&DGivinostat Update - Material
-
R&DJCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular DystrophyView PDF
-
FinancesPartial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025) (Japanese standard)